Skip to main content
Book cover

Principles and Practice of Urooncology pp 123–140Cite as

Radiotherapy in the Management of Testicular Cancers

  • 1020 Accesses

Abstract

Testicular cancers are the most common solid malignancies affecting males between the ages of 15 and 35 years, although it accounts for only about 1% of all cancers in men. Approximately 95% of testicular tumors are germ cell tumors (GCT). At diagnosis, 1–2% of cases are bilateral and 80% of patients are diagnosed at stage I. The risk factors for testicular cancers are family history, cryptorchidism, altered hormonal environment, low fertility, abnormal sperm analysis, and immunosuppression. For treatment purposes, two broad categories are recognized: pure seminoma (no non-seminomatous elements present) and all others, which together are termed non-seminomatous germ cell tumors (NSGCT). Seminoma is highly sensitive to chemotherapy and radiotherapy (RT). The prognosis of patients is generally good; cure is an expected outcome in the majority of cases, even with metastatic disease.

Keywords

  • Seminoma
  • Radiotherapy
  • Non-seminoma
  • Testicular tumors

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-56114-1_7
  • Chapter length: 18 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-56114-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   179.99
Price excludes VAT (USA)
Hardcover Book
USD   179.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 7.1
Fig. 7.2
Fig. 7.3
Fig. 7.4
Fig. 7.5
Fig. 7.6
Fig. 7.7

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.

    CrossRef  PubMed  Google Scholar 

  2. Heidenreich A, Weissbach L, German Testicular Cancer I. Bilateral germ cell cancer of the testis: a report of 11 patients with a long-term follow-up. BJU Int. 2001;87(3):278–80.

    CAS  CrossRef  PubMed  Google Scholar 

  3. Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, et al. Pure seminoma: a review and update. Radiat Oncol. 2011;6:90. doi:10.1186/1748-717X-6-90.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  4. Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Fare E, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol. 2015;26(4):657–68. doi:10.1093/annonc/mdu447.

    CAS  CrossRef  PubMed  Google Scholar 

  5. Pearce SM, Liauw SL, Eggener SE. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015;42(3):287–98. doi:10.1016/j.ucl.2015.04.003.

    CrossRef  PubMed  Google Scholar 

  6. Mottet N, Culine S, Iborra F, Avances C, Bastide C, Lesourd A, et al. Testicular tumors. Prog Urol. 2007;17(6):1035–45.

    CrossRef  PubMed  Google Scholar 

  7. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315–20.

    CAS  CrossRef  PubMed  Google Scholar 

  8. Djeffal C, Demailly M, Tillou X, Saint F, Petit J. Place of serum HCG assay in the follow-up of non-HCG-secreting testicular seminomas. Prog Urol. 2008;18(10):654–6. doi:10.1016/j.purol.2008.04.024.

    CAS  CrossRef  PubMed  Google Scholar 

  9. Hori K, Uematsu K, Yasoshima H, Yamada A, Sakurai K, Ohya M. Testicular seminoma with human chorionic gonadotropin production. Pathol Int. 1997;47(9):592–9.

    CAS  CrossRef  PubMed  Google Scholar 

  10. Pizzocaro G, Nicolai N, Salvioni R. Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis. World J Urol. 1994;12(3):113–9.

    CAS  CrossRef  PubMed  Google Scholar 

  11. Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v140–6. doi:10.1093/annonc/mdq176.

    CrossRef  PubMed  Google Scholar 

  12. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96. doi:10.1016/j.eururo.2007.12.024.

    CrossRef  PubMed  Google Scholar 

  13. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20(22):4448–52. doi:10.1200/JCO.2002.01.038.

    CrossRef  PubMed  Google Scholar 

  14. Kamba T, Kamoto T, Okubo K, Teramukai S, Kakehi Y, Matsuda T, et al. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol. 2010;17(12):980–7. doi:10.1111/j.1442-2042.2010.02645.x.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  15. Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology. 2000;55(1):102–6.

    CAS  CrossRef  PubMed  Google Scholar 

  16. Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011;22(4):808–14. doi:10.1093/annonc/mdq466.

    CAS  CrossRef  PubMed  Google Scholar 

  17. Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol. 1995;13(9):2255–62. doi:10.1200/jco.1995.13.9.2255.

    CAS  CrossRef  PubMed  Google Scholar 

  18. Horwich A, Alsanjari N, A’Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer. 1992;65(5):775–8.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  19. von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer. 1993;29A(14):1931–4.

    CrossRef  PubMed  Google Scholar 

  20. Ondrusova M, Ondrus D, Miskovska V, Kajo K, Szoldova K, Usakova V, et al. Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy. Int Urol Nephrol. 2015;47(7):1143–7. doi:10.1007/s11255-015-1002-4.

    CAS  CrossRef  PubMed  Google Scholar 

  21. Cohn-Cedermark G, Stahl O, Tandstad T. Swenoteca. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors – a review and the SWENOTECA experience. Andrology. 2015;3(1):102–10. doi:10.1111/andr.280.

    CAS  CrossRef  PubMed  Google Scholar 

  22. Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33(1):51–7. doi:10.1200/JCO.2014.56.2116.

    CrossRef  PubMed  Google Scholar 

  23. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354–65. doi:10.1093/jnci/dji278.

    CrossRef  PubMed  Google Scholar 

  24. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89(19):1429–39.

    CAS  CrossRef  PubMed  Google Scholar 

  25. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol. 2008;19(3):443–7. doi:10.1093/annonc/mdm540.

    CAS  CrossRef  PubMed  Google Scholar 

  26. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370–8. doi:10.1200/JCO.2006.10.5296.

    CrossRef  PubMed  Google Scholar 

  27. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513–23. doi:10.1200/JCO.2003.04.173.

    CAS  CrossRef  PubMed  Google Scholar 

  28. Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv. 2008;2(3):128–37. doi:10.1007/s11764-008-0054-1.

    CAS  CrossRef  PubMed  Google Scholar 

  29. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649–57. doi:10.1200/JCO.2010.29.9362.

    CrossRef  PubMed  Google Scholar 

  30. Buchholz TA, Walden TL, Prestidge BR. Cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma. Cancer. 1998;82(6):1126–33.

    CAS  CrossRef  PubMed  Google Scholar 

  31. Clasen J, Schmidberger H, Souchon R, Weissbach L, Hartmann M, Hartmann JT, et al. What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients. Strahlenther Onkol. 2009;185(6):349–54. doi:10.1007/s00066-009-1958-z.

    CrossRef  PubMed  Google Scholar 

  32. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53(3):497–513. doi:10.1016/j.eururo.2007.12.025.

    CrossRef  PubMed  Google Scholar 

  33. Mead GM, Fossa SD, Oliver RT, Joffe JK, Huddart RA, Roberts JT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103(3):241–9. doi:10.1093/jnci/djq525.

    CrossRef  PubMed  Google Scholar 

  34. Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R, et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer. 2004;90(12):2305–11. doi:10.1038/sj.bjc.6601867.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Martin JM, Joon DL, Ng N, Grace M, Gelderen DV, Lawlor M, et al. Towards individualised radiotherapy for Stage I seminoma. Radiother Oncol. 2005;76(3):251–6. doi:10.1016/j.radonc.2005.08.005.

    CrossRef  PubMed  Google Scholar 

  36. Taylor A, Rockall AG, Reznek RH, Powell ME. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(5):1604–12. doi:10.1016/j.ijrobp.2005.05.062.

    CrossRef  PubMed  Google Scholar 

  37. Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys. 2005;63(4):1262–9. doi:10.1016/j.ijrobp.2005.07.952.

    CrossRef  PubMed  Google Scholar 

  38. Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(4):1146. doi:10.1200/jco.1999.17.4.1146.

    CAS  CrossRef  PubMed  Google Scholar 

  39. McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology. 2010;254(1):31–46. doi:10.1148/radiol.2541090361.

    CrossRef  PubMed  Google Scholar 

  40. Dinniwell R, Chan P, Czarnota G, Haider MA, Jhaveri K, Jewett M, et al. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;74(3):844–51. doi:10.1016/j.ijrobp.2008.09.026.

    CrossRef  PubMed  Google Scholar 

  41. Detti B, Livi L, Scoccianti S, Gacci M, Lapini A, Cai T, et al. Management of Stage II testicular seminoma over a period of 40 years. Urol Oncol. 2009;27(5):534–8. doi:10.1016/j.urolonc.2008.07.034.

    CrossRef  PubMed  Google Scholar 

  42. Hunter M, Peschel RE. Testicular seminoma. Results of the Yale University experience, 1964-1984. Cancer. 1989;64(8):1608–11.

    CAS  CrossRef  PubMed  Google Scholar 

  43. Thomas GM. Is “optimal” radiation for stage I seminoma yet defined? J Clin Oncol. 1999;17(9):3004–5.

    CAS  PubMed  Google Scholar 

  44. Zwahlen DR, Martin JM, Millar JL, Schneider U. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2008;70(3):853–8. doi:10.1016/j.ijrobp.2007.10.007.

    CrossRef  PubMed  Google Scholar 

  45. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200–8. doi:10.1200/JCO.2005.08.003.

    CrossRef  PubMed  Google Scholar 

  46. Coleman JM, Coleman RE, Turner AR, Radstone CR, Champion AE. The management and clinical course of testicular seminoma: 15 years’ experience at a single institution. Clin Oncol (R Coll Radiol). 1998;10(4):237–41.

    CAS  CrossRef  Google Scholar 

  47. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003;21(6):1101–6. doi:10.1200/JCO.2003.06.065.

    CrossRef  PubMed  Google Scholar 

  48. Patterson H, Norman AR, Mitra SS, Nicholls J, Fisher C, Dearnaley DP, et al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol. 2001;59(1):5–11.

    CAS  CrossRef  PubMed  Google Scholar 

  49. Arranz Arija JA, Garcia del Muro X, Guma J, Aparicio J, Salazar R, Saenz A, et al. E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience. Ann Oncol. 2001;12(4):487–91.

    CAS  CrossRef  PubMed  Google Scholar 

  50. Domont J, Massard C, Patrikidou A, Bossi A, de Crevoisier R, Rose M, et al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol. 2013;31(5):697–705. doi:10.1016/j.urolonc.2011.04.004.

    CAS  CrossRef  PubMed  Google Scholar 

  51. Garcia-del-Muro X, Maroto P, Guma J, Sastre J, Lopez Brea M, Arranz JA, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol. 2008;26(33):5416–21. doi:10.1200/JCO.2007.15.9103.

    CAS  CrossRef  PubMed  Google Scholar 

  52. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–68. doi:10.1016/j.eururo.2015.07.044.

    CrossRef  PubMed  Google Scholar 

  53. van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer. 2008;98(12):1894–902. doi:10.1038/sj.bjc.6604280.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  54. de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer. 1998;78(10):1350–5.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  55. Feldman DR, Motzer RJ, Bajorin DF. Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors? Nat Clin Pract Urol. 2008;5(2):78–9. doi:10.1038/ncpuro0999.

    CrossRef  PubMed  Google Scholar 

  56. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22(5):1054–61. doi:10.1093/annonc/mdq575.

    CAS  CrossRef  PubMed  Google Scholar 

  57. Oliver RT, Freedman LS, Parkinson MC, Peckham MJ. Medical options in the management of stages 1 and 2 (N0-N3, M0) testicular germ cell tumors. Urol Clin North Am. 1987;14(4):721–30.

    CAS  PubMed  Google Scholar 

  58. Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987;2(8554):294–8.

    CAS  CrossRef  PubMed  Google Scholar 

  59. Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol. 2010;21(6):1296–301. doi:10.1093/annonc/mdp473.

    CAS  CrossRef  PubMed  Google Scholar 

  60. Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol. 2013;31(28):3490–3. doi:10.1200/JCO.2012.47.6010.

    CrossRef  PubMed  Google Scholar 

  61. Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v147–54. doi:10.1093/annonc/mdq177.

    CrossRef  PubMed  Google Scholar 

  62. Sheinfeld J, Herr HW. Role of surgery in management of germ cell tumor. Semin Oncol. 1998;25(2):203–9.

    CAS  PubMed  Google Scholar 

  63. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966–72. doi:10.1200/JCO.2007.12.0899.

    CAS  CrossRef  PubMed  Google Scholar 

  64. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27(13):2122–8. doi:10.1200/JCO.2008.18.8953.

    CrossRef  PubMed  Google Scholar 

  65. Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol. 2007;25(35):5597–602. doi:10.1200/JCO.2007.12.0808.

    CrossRef  PubMed  Google Scholar 

  66. Frohlich MW, Small EJ. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am. 1998;25(3):451–9.

    CAS  CrossRef  PubMed  Google Scholar 

  67. Peckham MJ. Surveillance following orchiectomy for clinicaL stage I testicular germ-cell malignancy. Acta Urol Belg. 1985;53(2):283–98.

    CAS  PubMed  Google Scholar 

  68. Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol. 1994;151(1):72–7; discussion 7–8.

    Google Scholar 

  69. Chevreau C, Mazerolles C, Soulie M, Gaspard MH, Mourey L, Bujan L et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol. 2004;46(2):209–14; discussion 14-–5. doi:10.1016/j.eururo.2004.03.022.

  70. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol. 1994;152(1):111–3; discussion 114.

    Google Scholar 

  71. Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol. 2000;37(5):582–94.

    CAS  CrossRef  PubMed  Google Scholar 

  72. Mead GM, Stenning SP. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol). 1997;9(4):207–9.

    CAS  CrossRef  Google Scholar 

  73. Oldenburg J, Alfsen GC, Waehre H, Fossa SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer. 2006;94(6):820–7. doi:10.1038/sj.bjc.6603014.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  74. Motzer RJ, Bajorin DF, Bosl GJ. “Poor-risk” germ cell tumors: current progress and future directions. Semin Oncol. 1992;19(2):206–14.

    CAS  PubMed  Google Scholar 

  75. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28(10):1706–13. doi:10.1200/JCO.2009.25.1561.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  76. Baniel J, Roth BJ, Foster RS, Donohue JP. Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors. Cancer. 1995;75(12):2897–903.

    CAS  CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Adana Dr Turgut Noyan Research and Treatment Center, Başkent University, Adana, Turkey

    Berna Akkus Yildirim M.D. & Cem Onal M.D.

Authors
  1. Berna Akkus Yildirim M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cem Onal M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Berna Akkus Yildirim M.D. .

Editor information

Editors and Affiliations

  1. Chair and Professor, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    MD Gokhan Ozyigit

  2. Chair and Professor, Department of Radiation Oncology, Koc University, Istanbul, Turkey

    MD Ugur Selek

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Yildirim, B.A., Onal, C. (2017). Radiotherapy in the Management of Testicular Cancers. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)